脑胶质瘤个体化治疗和分子诊断的研究进展  

Research progress on individualized treatment and molecular diagnosis for brain glioma

作　　者：周泉[1] 李艳[1] 童永清[1] 

机构地区：[1]武汉大学人民医院检验科,湖北武汉430060

出　　处：《职业与健康》2016年第3期426-429,共4页Occupation and Health

基　　金：武汉大学人民医院国家临床重点专科建设项目(财社[2010]305号)

摘　　要：脑胶质瘤是颅内常见恶性肿瘤,发病率、复发率、死亡率高但治愈率低。病因不明,有多种起源假说,目前学者倾向于脑胶质瘤干细胞假说。由于其呈浸润性生长,因此多主张联合治疗,术后配以化疗和放疗延缓复发与延长患者生存期。由于脑胶质瘤分子生物学的发展,使得分子靶向药物可以用于临床。常见分子靶标的检测有1p/19q缺失、MGMT甲基化、EGFR-PI3K通路激活和IDH基因突变。目前以分子诊断为基础的个体化医疗已成为临床医生治疗脑胶质瘤的首选方法。Brain glioma is a kind of common intracranial malignant tumors, which is characterized by high incidence rate, high recurrence rate, high morbidity rate and low cure rate. The cause of disease is unknown and it has several kinds of hypothesis, some scholars tend to believe the hypothesis of glioma stem cell at present. Because of its invasive growth, combination therapy is the best method that is chemotherapy accompanied by radiotherapy after surgery. The method can delay recurrence and prolong survival of patients. With the progress of molecular biology, the molecular targeted drugs are applied in clinic. Common molecular targets detections include deletion of 1p/19q, methylation of MGMT activation of EGFR-PI3K and mutation of IDH. Personalized medicine based on the molecular diagnosis has become the preferred method for clinicians to the treatment of brain glioma.

关 键 词：脑胶质瘤 个体化治疗 分子诊断 

分 类 号：R134.2[医药卫生—劳动卫生]